Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity,